Abstract
Purpose To explore the role of stone fragment and ureteric stent in process of intermittent gross hematuria (IGH), discuss the definition of ureteral stent related symptoms (USS) in a setting of lithotripsy and clinical outcomes of IGH.
Methods Between January 2018 and July 2019, patients with completed one month follow up after lithotripsy were collected. Based on whether occurrence of IGH, demographics, stent information and clinical outcomes were mainly analyzed.
Results A total of 258 consecutive patients were eventually analyzed, among which 97 patients (37.6%) suffered from IGH. Compared to patients without symptom of IGH, preoperative potassium level (3.89±0.43mmol/L vs. 4.02±0.42mmol/L, p=0.01), initial stone free rate (SFR, 50.52% vs. 68.32%, p=0.007) and potassium citrate application (11.34% vs. 4.55%, p=0.04) were found statistically different in univariate analysis. In multivariate logistic analysis, preoperative potassium level (OR: 0.39, CI: 0.19-0.76, p=0.007), potassium citrate (OR: 2.96, CI: 1.07-8.73, p=0.04), initial SFR (OR: 0.42, CI: 0.24-0.74, p<0.001), and hospital stay (OR: 0.94, CI: 0.89-0.99, p=0.045) were independent risk factors, rather than stent size and stent position. Hemoglobin change, stone area reduction and SFR in one-month follow-up were similar between groups, but more outpatient consultations were found in hematuria group (20 vs. 3, p<0.001), among which 2 patients were readmitted for severe ongoing hematuria.
Conclusions Stone fragment, rather the size or length of ureteral stent, is the independent risk factors of IGH. Definition of USS is not suitable for IGH after lithotripsy, and a comprehensive inform and enough rest would reduce the unnecessary medical consultations.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NA.
Funding Statement
No external funding was received.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Availability of all data referred to in the manuscript were included as supplementary documents.
Abbreviations
- IGH
- intermittent gross hematuria
- USS
- ureteral stent related symptoms
- LUTS
- lower urinary tract symptoms
- PCNL
- percutaneous nephrolithotomy
- RIRS
- flexible retrograde intrarenal surgery
- URSL
- transurethral ureteroscope lithotripsy
